Endoglin as a possible marker of atorvastatin treatment benefit in atherosclerosis

Pharmacological Research

Volumn 64, Issue 1, 2011, Pages 53-59

  Rathouska, Jana ^a   Vecerova, Lenka ^a   Strasky, Zbynek ^a   Slanarova, Martina ^a   Brcakova, Eva ^a   Mullerova, Zuzana ^a   Andrys, Ctirad ^b   Micuda, Stanislav ^c   Nachtigal, Petr ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

ALK 1; Atherosclerosis; Atorvastatin; Endoglin; p Smad1; VEGF

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; ATORVASTATIN; BIOLOGICAL MARKER; ENDOGLIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SMAD1 PROTEIN; VASCULOTROPIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ACTIVIN RECEPTORS, TYPE I; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIOMARKERS, PHARMACOLOGICAL; BLOOD; CHOLESTEROL; CHOLESTEROL, DIETARY; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; FEMALE; HEPTANOIC ACIDS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHORYLATION; PLAQUE, ATHEROSCLEROTIC; PYRROLES; RECEPTORS, LDL; SINUS OF VALSALVA; SMAD1 PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79957754160     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2011.03.008     Document Type: Article

References (41)

1. Lopez-Novoa JM, Bernabeu C. The physiological role of endoglin in the cardiovascular system. Am J Physiol Heart Circ Physiol 2010;299:H959-74.
2. Bot PT, Hoefer IE, Sluijter JP, van Vliet P, Smits AM, Lebrin F, et al. Increased expression of the transforming growth factor-beta signaling pathway, endoglin, and early growth response-1 in stable plaques. Stroke 2009;40:439-47.
3. St-Jacques S, Cymerman U, Pece N, Letarte M. Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-beta binding protein of endothelial and stromal cells. Endocrinology 1994;134:2645-57.
4. Lastres P, Bellon T, Cabanas C, Sanchez-Madrid F, Acevedo A, Gougos A, et al. Regulated expression on human macrophages of endoglin, an arg-gly-aspcontaining surface antigen. Eur J Immunol 1992;22:393-7.
5. Tian F, Zhou AX, Smits AM, Larsson E, Goumans MJ, Heldin CH, et al. Endothelial cells are activated during hypoxia via endoglin/alk-1/smad1/5 signaling in vivo and in vitro. Biochem Biophys Res Commun 2010;392:283-8.
6. ten Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis 2008;11:79-89.
7. Piao M, Tokunaga O. Significant expression of endoglin (cd105), tgfbeta-1 and tgfbeta r-2 in the atherosclerotic aorta: an immunohistological study. J Atheroscler Thromb 2006;13:82-9.
8. Conley BA, Smith JD, Guerrero-Esteo M, Bernabeu C, Vary CP. Endoglin, a tgf-beta receptor-associated protein, is expressed by smooth muscle cells inhuman atherosclerotic plaques. Atherosclerosis 2000;153:323-35. (Pubitemid 32120331)
9. Nachtigal P, Vecerova L, Pospisilova N, Micuda S, Brcakova E, Navarro Hernandez E, et al. Endoglin co-expression with enos, smad2 and phosphorylated smad2/3 in normocholesterolemic and hypercholesterolemic mice: an immunohistochemical study. Histol Histopathol 2009;24:1499-506.
10. Nachtigal P, Pospisilova N, Vecerova L, Micuda S, Brcakova E, Pospechova K, et al. Atorvastatin increases endoglin, smad2, phosphorylated smad2/3 and enos expression in apoe/ldlr double knockout mice. J Atheroscler Thromb 2009;16:265-74.
11. PowersRW,Jeyabalan A, Clifton RG,VanDorsten P, Hauth JC, KlebanoffMA,et al. Soluble fms-like tyrosine kinase 1 (sflt1), endoglin and placental growth factor (plgf) in preeclampsia among high risk pregnancies. PLoS One 2010;5:e13263.
12. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005. (Pubitemid 44343543)
13. Blazquez-Medela AM, Garcia-Ortiz L, Gomez-Marcos MA, Recio-Rodriguez JI, Sanchez-Rodriguez A, Lopez-Novoa JM, et al. Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med 2010;8:86.
14. Blanco FJ, Santibanez JF, Guerrero-Esteo M, Langa C, Vary CP, Bernabeu C. Interaction and functional interplay between endoglin and alk-1, two components of the endothelial transforming growth factor-beta receptor complex. J Cell Physiol 2005;204:574-84. (Pubitemid 40934653)
15. Yao Y, Zebboudj AF, Torres A, Shao E, Bostrom K. Activin-like kinase receptor 1 (alk1) in atherosclerotic lesions and vascular mesenchymal cells. Cardiovasc Res 2007;74:279-89. (Pubitemid 46517503)
16. Yao Y, Shao ES, Jumabay M, Shahbazian A, Ji S, Bostrom KI. High-density lipoproteins affect endothelial bmp-signaling by modulating expression of the activin-like kinase receptor 1 and 2. Arterioscler Thromb Vasc Biol 2008;28:2266-74.
17. Tassone E, Maran C, Masola V, Bradaschia A, Garbisa S, Onisto M. Antidepressant hyperforin up-regulates vegf in cns tumour cells. Pharmacol Res 2011;63:37-43.
18. Holm PW, Slart RH, Zeebregts CJ, Hillebrands JL, Tio RA. Atherosclerotic plaque development and instability: a dual role for vegf. Ann Med 2009;41:257-64.
19. Walshe TE, Dole VS, Maharaj AS, Patten IS, Wagner DD, D'Amore PA. Inhibition of vegf or tgf-β signaling activates endothelium and increases leukocyte rolling. Arterioscler Thromb Vasc Biol 2009;29:1185-92.
20. Zhou Q, Liao JK. Pleiotropic effects of statins-basic research and clinical perspectives. Circ J 2010;74:818-26.
21. Aydin S, Uzun H, Sozer V, Altug T. Effects of atorvastatin therapy on protein oxidation and oxidative DNA damage in hypercholesterolemic rabbits. Pharmacol Res 2009;59:242-7.
22. Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij J, van der Hoorn J, Princen HM, et al. Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 2007;27:1706-21. (Pubitemid 47207165)
23. Nachtigal P, Semecky V, Kopecky M, Gojova A, Solichova D, Zdansky P, et al. Application of stereological methods for the quantification of vcam-1 and icam-1 expression in early stages of rabbit atherogenesis. Pathol Res Pract 2004;200:219-29. (Pubitemid 38950433)
24. Brcakova E, Fuksa L, Cermanova J, Kolouchova G, Hroch M, Hirsova P, et al. Alteration of methotrexate biliary and renal elimination during extrahepatic and intrahepatic cholestasis in rats. Biol Pharm Bull 2009;32:1978-85.
25. Ma X, Labinaz M, Goldstein J, Miller H, Keon WJ, Letarte M, et al. Endoglin is overexpressed after arterial injury and is required for transforming growth factor-beta-induced inhibition of smooth muscle cell migration. Arterioscler Thromb Vasc Biol 2000;20:2546-52.
26. Eussen SR, Rompelberg CJ, Andersson KE, Klungel OH, Hellstrand P, Oste R, et al. Simultaneous intake of oat bran and atorvastatin reduces their efficacy to lower lipid levels and atherosclerosis in ldlr-/-mice. Pharmacol Res 2011.
27. Santibanez JF, Letamendia A, Perez-Barriocanal F, Silvestri C, Saura M, Vary CP, et al. Endoglin increases enos expression by modulating smad2 protein levels and smad2-dependent tgf-beta signaling. J Cell Physiol 2007;210:456-68. (Pubitemid 44956891)
28. Blaha M, Cermanova M, Blaha V, Jarolim P, Andrys C, Blazek M, et al. Elevated serum soluble endoglin (scd105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia. Atherosclerosis 2008;197:264-70. (Pubitemid 351273248)
29. De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D'Anna R. Endoglin, plgf and sflt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 2008;87:837-42.
30. Perez-Gomez E, Del Castillo G, Juan Francisco S, Lopez-Novoa JM, Bernabeu C, Quintanilla M. The role of the tgf-beta coreceptor endoglin in cancer. Scientific- WorldJournal 2010;10:2367-84.
31. Ley K, Huo Y. Vcam-1 is critical in atherosclerosis. J Clin Invest 2001;107:1209-10. (Pubitemid 32494533)
32. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, Iiyama M, et al. A major role for vcam-1, but not icam-1, in early atherosclerosis. J Clin Invest 2001;107:1255-62. (Pubitemid 32494542)
33. Ramos CL, Huo Y, Jung U, Ghosh S, Manka DR, Sarembock IJ, et al. Direct demonstration of p-selectin- and vcam-1-dependent mononuclear cell rolling in early atherosclerotic lesions of apolipoprotein e-deficient mice. Circ Res 1999;84:1237-44. (Pubitemid 29270037)
34. Utsumi K, Kawabe M, Hirama A, Ueda K, Kamada Y, Arii K, et al. Effects of selective ldl apheresis on plasma concentrations of icam-1, vcam-1 and p-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis. Clin Chim Acta 2007;377:198-200. (Pubitemid 44908253)
35. Hajilooi M, Sanati A, Ahmadieh A, Ghofraniha A, Massoud A. Circulating icam- 1, vcam-1, e-selectin, p-selectin, and tnfrii in patients with coronary artery disease. Immunol Invest 2004;33:263-75. (Pubitemid 39299313)
36. Luc G, Arveiler D, Evans A, Amouyel P, Ferrieres J, Bard JM, et al. Circulating soluble adhesion molecules icam-1 and vcam-1 and incident coronary heart disease: the prime study. Atherosclerosis 2003;170:169-76. (Pubitemid 37083576)
37. Demerath E, Towne B, Blangero J, Siervogel RM. The relationship of soluble icam-1, vcam-1, p-selectin and e-selectin to cardiovascular disease risk factors in healthy men and women. Ann Hum Biol 2001;28:664-78. (Pubitemid 33066057)
38. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642-9. (Pubitemid 43865232)
39. Lopez-Novoa JM. Soluble endoglin is an accurate predictor and a pathogenic molecule in pre-eclampsia. Nephrol Dial Transplant 2007;22:712-4. (Pubitemid 46351677)
40. Bourdeau A, Faughnan ME, Letarte M. Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia. Trends Cardiovasc Med 2000;10:279-85. (Pubitemid 32422105)
41. Hawinkels LJ, Kuiper P, Wiercinska E, VerspagetHW,Liu Z, Pardali E, et al. Matrix metalloproteinase-14 (mt1-mmp)-mediated endoglin shedding inhibits tumor angiogenesis. Cancer Res 2010;70:4141-50.